# Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

> **NCT01838044** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 180 (actual)

## Conditions studied

- Chronic Low Back Pain With a Neuropathic Component

## Interventions

- **DRUG:** pregabalin and celecoxib
- **DRUG:** Placebo and celecoxib

## Key facts

- **NCT ID:** NCT01838044
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 180 (ACTUAL)
- **Why stopped:** Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational feasibility. Study was not terminated for reasons of safety/efficacy.
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838044, "Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01838044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*